{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-23-000411","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.002080+00:00","generated_at":"2026-06-19T13:13:08.219973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Standard BioTools Q4 rev $27M (+8.3% seq); FY22 rev $97.9M vs $130.6M; guides 2023 flat-to-mod growth","bullets":["Q4 2022 GAAP revenue $27.0M; core product/service rev $26.8M, up 8.3% sequentially.","Full year GAAP revenue $97.9M (down from $130.6M in 2021); core rev $94.5M vs $111.6M.","Q4 product margin GAAP 40.9% (+620 bps seq), non-GAAP 52.9% (+520 bps); opex down 16% seq to $32.3M.","2023 guidance: flat-to-moderate core rev growth; GAAP opex ~$118-123M (20% reduction); Q4 GAAP gross margin 52-55%.","Cash $165.8M at year-end; expects positive free cash flow by end of 2024; restructuring to cut >$30M opex annually."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-23-000411","json":"https://secwatch.observer/filing/0000950142-23-000411.json","markdown":"https://secwatch.observer/filing/0000950142-23-000411.md","text":"https://secwatch.observer/filing/0000950142-23-000411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/eh230318897_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:13:08.219973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44a960de806c163b867dc711487983fcac35e7fe","claim":"STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue $97.9 million. Guidance reaffirmed.","evidence_excerpt":"GAAP revenues were $97.9 million compared to $130.6 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$97.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9a80f6dc7024d3f5583727e55425f1582e0cb93e","claim":"STANDARD BIOTOOLS INC. updated its 2023 guidance (initiated).","evidence_excerpt":"For 2023, Standard BioTools expects flat-to-moderate growth in core product and service revenues relative to 2022 core product and service revenues of $94.5 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f3e25fc1c138e87693307737a4d9ec7e8cb90a8b","claim":"STANDARD BIOTOOLS INC. reported the three months ended December 31, 2022 results: revenue $27.0 million. Guidance reaffirmed.","evidence_excerpt":"Fourth quarter 2022 GAAP revenues were $27.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$27.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}